Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Leukocytes01:27

Disorders of Leukocytes

2.5K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
2.5K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

4.3K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
4.3K
Lineage Commitment01:21

Lineage Commitment

4.6K
Commitment is the  process whereby stem cells:
4.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnostic and therapeutic challenges in claudin 18.2-positive gastric cancer treated with zolbetuximab: Intrapatient heterogeneity or secondary loss of expression?

Journal of cancer research and clinical oncology·2026
Same author

Things that drive Editors crazy: jargon, unnecessary abbreviations, abusing decimals and a few more.

Leukemia·2025
Same author

Mpox in people with haematological cancers.

Leukemia·2024
Same author

Measuring financial distress in German cancer patients: development and validation of the Financial Distress of Cancer Assessment Tool (FIAT).

ESMO open·2024
Same author

The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial.

Leukemia·2023
Same author

The German Network for Personalized Medicine to enhance patient care and translational research.

Nature medicine·2023
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
See all related articles

Related Experiment Video

Updated: Apr 15, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.9K

[Chronic myelogenous leukemia].

A Hochhaus1, P La Rosée, E Eigendorff

  • 1Abteilung Hämatologie/Onkologie, Universitätsklinikum Jena, Erlanger Allee 101, 07740, Jena, Deutschland, andreas.hochhaus@med.uni-jena.de.

Der Internist
|April 11, 2015
PubMed
Summary
This summary is machine-generated.

Second-generation tyrosine kinase inhibitors (TKIs) offer improved molecular remissions for chronic myelogenous leukemia (CML) patients. Investigational therapies, including interferon alpha, aim to induce immune responses for potential long-term remission and curability.

More Related Videos

A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model
08:00

A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model

Published on: October 14, 2016

21.6K
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

861

Related Experiment Videos

Last Updated: Apr 15, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.9K
A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model
08:00

A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model

Published on: October 14, 2016

21.6K
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

861

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Context:

  • Tyrosine kinase inhibitors (TKIs) have revolutionized chronic myelogenous leukemia (CML) treatment.
  • Second-generation TKIs like nilotinib and dasatinib demonstrate superior efficacy over imatinib.
  • Monitoring CML remission status relies on cytogenetics and polymerase chain reaction (PCR).

Purpose:

  • To evaluate the impact of second-generation TKIs on CML patient outcomes.
  • To explore novel therapeutic strategies, such as interferon alpha, for CML.
  • To assess the potential for treatment-free remission and curability in CML.

Summary:

  • Second-generation TKIs achieve faster and deeper molecular remissions in CML compared to imatinib, with distinct side effect profiles.
  • Regular monitoring via cytogenetics and PCR is crucial for assessing treatment response.
  • Interferon alpha is being investigated for its potential to induce immune responses against the CML clone, aiming for long-term remission.

Impact:

  • Improved patient prognosis and outcomes in CML.
  • Advancement towards potential curability of CML.
  • Development of innovative treatment approaches through collaborative care and early adoption of new therapies.